Quick Search

  Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home

 
Brands
  Pharmacist Nutriceuticals®
  USA Best®
  USA LABORATORIES®
  USA SPORTS LABS®
Products
  Health Concerns
  Sexual Health
  Specialty Supplements
  Vitamins & Minerals
  --------------------------------------------
  Weight Loss
  --------------------------------------------
  Children's
  --------------------------------------------
  Female
  Male
  --------------------------------------------
  Sports & Athletic Nutrition
  Extreme Hardcore Body Building
  Body Shaping
  Amino Acids
  Proteins
  Carbohydrates
  --------------------------------------------
  Food Bars
  --------------------------------------------
  Branded Ingredients
  --------------------------------------------
  Press Releases
  --------------------------------------------
  Employment
  Company Policy
2323 NITRO INSULIN LIQUID AMINO™ [click to enlarge]
USASLLPF16O - 17#

MSRP: $39.99
Internet Direct: $34.99

Bottles:


16 fl oz Liquid Amino Acids
with Chromium Picolinate!


"Nutrition, Hardcore Athletes Get It!"


Pharmacist References:

L-Glutamine References:
1. Damrau F. Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief. j Am Gariatric Soc 1962;10(5):426-30.
2. Feinblatt HM, Gant JC. Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination. J Maine Med Assoc Mar 1958.
3. Zello GA, Wykes LF, Ball RO, et al. Recent advances in methods of assessing dietary amino acid requirements for adult humans. J Nutr 1995;125:2907-15.

L-Alanine References:
1. Damrau F. Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief. j Am Gariatric Soc 1962;10(5):426-30.
2. Feinblatt HM, Gant JC. Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination. J Maine Med Assoc Mar 1958.
3. Zello GA, Wykes LF, Ball RO, et al. Recent advances in methods of assessing dietary amino acid requirements for adult humans. J Nutr 1995;125:2907-15.

L-Glycine References:
1. Damrau F. Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief. J Am Geriatric Soc 1962;10(5):426-30.
2. Feinblatt HM, Gant JC. Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination. j Maine Med Assoc Mar 1958.

L-Methionine References:
1. Muller f et al. Elevated plasma concentration of reduced homocysteine in patients with Human Immunodeficiency Virus infection. Am J Clin Nutr 1996;242-46.
2. Revillard JP. Lipid peroxidation in Human immunodefeciency Virus infection. J Acquired Immunode Synd 1992;5:637-38.
3. Singer P et al. Nutritional aspects of the Acquired Immunodefeciency Syndrome. Am J Gastroenter 1992;87:265-73.
4. Tan SV, Guiloff RJ. Hypothesis on the pathongenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiat 1998 65:23-25.
5. Keating JN et al. Evidences of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. Lancet 1991;337:935-39.
6. Dorfman D, DiRocco A, Simpson D, et al. Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial. AIDS 1997;11:1066-67.
7. Smythies JR, Halsey JH. Treatment of Parkinson's disease with l-methionine. Shouth Med J 1974;77:1577.
8. Uden S, Bilton D, Nathan L, et al. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. Aliment Pharmacol Ther 1990;4:357-71.
9. Shaw GM, Velle EM, Schaffer DM. Is dietary intake of methionine associated with a reduction in risk for neural tube defect-associated pregnancies? Teratology
1997;56:295-99.
10. Toborek M, Hennig B. Is methionine an atherogenci amino acid? J Optimalt Nutr 1994;3(2):80-8.
11. Leach FN, Braganza JM. Methionine is important in treatment of chronic pancreatitis. Br Med J 1998;316:474 [letter].

L-Phenylalanine References:
1. Sabeli HC. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. J Clin Psychaiatry 1986;47:66-70.
2. Fischer E. et at. Therapy of depression by phenylalanine. Arzeimittelforsch 1975;25:132.
3. Heller B et al. Therapeutic action of D-phenylalanine in Parkinson's disease. Arzeimittelforsch 1976;26:577-79.
4. Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of itractable pain. Pain Res Ther 1983;5:305-8.
5. Anonymous. Phenylanine fails to help chronic back pain patients. Family Pract News 1987;17(3):37.

Vitamin B6 References:
1. Keniston RC, Nathan PA, Leklem JE, Lockwood Rs. Vitamin B6, vitamin C, and carpal tunnel syndrome. J Occup Environ Med 1997;39:949-59.
2. Franzblau A, Rock CL, Werner RA, et al. The relationship of vitamin B6 status to median nerve function and carpal tunnel syndrome among active industrial workers. J Occup Environ Med 1996;38:485-91.
3. Smith GP, Rudge PJ, Peters TJ. Biochemical studies of pyridoxal and pyridoxal phosphate status and therapeutic trial of pyridoxine in patients with carpal tunnel syndrome. Ann Neurol 1984;15:104-107.
4. Gaby AR. Literature review & commentary. Townsend Letter for Doctors June 1990;338-39.
5. Parry G, Bredesen DE. Sensory neuropath with low-dose pyridoxine. Neurology 1985;35:1466-68.
6. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N England Med 1983;309(8):445-48.

L-Arginine References:
1. Besset A, Bonardet A, Rondouin G, et al. Increase in sleep related GH and Pri secretion after chron. argnine aspartate adminstration in man. Acta Endocrinologica 1982;99:18-23.
2. Elam RP. Morphological changes in adult males from resistance exercise and amino acid supplementation. J Sports Med Phys Fitness 1988;28:35-39.
3. Schacter A, Goldman JA, Zukerman Z. Treatment of oligospermia with the amino acid arginine. J Urol 1973;110:311-13.
4. Pryor JP, Blandy JP, Evans P, et al. Controlled clinical trial of arginine for infertile men with loigozoospermia. Br J Urol 1978;50:47059.
5. Barbul A, Rettura G, Levenson SM, et al. Wound healing and thymotropic effects argine: a pituitary mechanism of action. Am J Clin Nutr 1983;37:786-94.
6. Kirk SJ, Hurson M, Regan MC, et al. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 1993;114:155-60.
7. Kohls KJ, Kies C, Fox HM. Serum lipid levels of humans given argine, lysine and tryptophan supplements without food. Nutr Rep Internat 1987;35:5-13.
8. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol
1997;29:479-85.
9. Smith SD, Wheeler MA, Foster HE Jr. Weiss RM. Improvement in interstitial cystitis symptom score during treatment with oral K-arginine. J Urol 1997;158:703-8.
10. Park KGM. The immunological and metabolic effects of L-arginine in human cancer. Proc Nutr Sci 1993;52:387-401.
11. Takeda Y, Tominga T, Tei N, et al. Inhibitory effect of L-arginine on growth fo rat mammary tumor induced by 7, 12, Dimethylbenz(a)anthracine. Cancer Res
1975;35:390-93.
12. Brittenden J, Park KGM, Heys SD, et al. L-arginine stimulates host defenses in patients with breast cancer. Surgery 1994;115:205-12.

L-Cysteine References:
1. Salim AS. Sulfhydryl-containing agents in the treatment of gastric bleeding induced by nonsteroidal anti-inflammatory drugs. Can j Surgery 1993;36:53-58.
2. Droge W, Eck HP, Gander H, Mihm S. Modulation of lymphocyte functions and immune response by cysteine and cysteine derivatives. Am J Med
1991;91(suppl 3C): 140S-44S.
3. Eck HP, Gander H, Hartmann M, et al. Biol Chem Hoppe Seyler 1989;370:101-8.
4. Droge W, Eck HP, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction--a rationale for treatment with N-acteylcysteine. Immunol Today 1992;13:211-14.
5. Droge W. Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with N-acetyl-cysteine. Pharmacol 1993;46:61-65.
6. Kleinveld HA, Demacker PNM, Stalenhoef AFH. Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy sugjects. Eur J Clin Pharmacol 1992;639-42.
7. Olney JW, Ho O-L. Brain damage in infant mice following oral intake of glutamante, aspartate or cysteine. Nature 1970;227:609-10 [letter].

L-Carnitine References:
1. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic effica of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-
2.Giamberardino MA et al. Effects of prolonged L-carnitine adminstration on delayed muscle pain an CK release after eccentric effort. Int J Sports Med 1996;17:320-24.
3. Green RE, Levine AM, Gunning MJ. The effect of L-cartine supplementation on lean body mass male amateur body builders. J AM, Dietet Assoc 1997;(syook):A-72.
4. Murray MT. The many benefits of carnitine. Am J Natural Med 1996;3:6-14 [review].
5. Dal Negro R, Pomari G, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabo and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1986;24:453-56.
6. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1988;26:269-72.
7. Dipalma JR. Carnitine deficiency. Am Family Phys 1988;38:243-51.
8. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.
9. Del Favero A. Carnitine and gangliosides. Lancet 1988;ii:337 [letter].
10. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure-experimental and clinical study. Jpn Circ J 1992;56:86-94.

Vitamin B1 References:
1. Cheraskin E, Ringsdorf WM, Medford FH, Hicks BS. The "ideal" daily vitamin B1 intake Oral Med 1978;33:77-79.

Vitamin B2 References:
1. Bhat Nutritional status of thiamine, riboflavin and pyridoxine in catarct patients. Nutr Rep Inter 1987;36:685-92.

Folic Acid References:
1.Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. JAMA 1995;274:1698-17.
2. Shaw GM, O'Malley CD, Wasserman CR, et al. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deciciencies among offspring. Am J Med Gentetics 1995;59:536-45.
3. Tolarova M. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. Lancet 1982;ii:217 [letter].
4. Shaw GM, Lammer EF, Wasserman CR, et al. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 14995;345:393-96.
5. Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996;143:1229-34.
6. Russel RM. A minimum of 13,500 deaths annually from coronary artery disease could be prevented by increasing folate intake to reduce homocysteine levels. JAMA 1996;274:1828-29.
7. Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. Am J Clin Nutr 1999;69:564-71.
8. Butterworth CE Jr, Tamua T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353-58.
9. Wald NJ, Bower C. Folic acid, pernicious anaemia, and prevention of neural tube defects. Lancet 1994;343:307.
10. Russell RM, Golner BB, Krasinski SD, et al. Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid. J Lab Clin Med 1988;112:458-63.
11. Russell RM, Dutta SK, Oaks EV, et al. Impariment of folic acid absorption by oral pancreatic extracts. Dig Dis Sci 1980;25:369-73.

Paba References:
1. Wiesel LL et al. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. Am J Med Sci 1951;222:243-48.
2. Sieve BF. The clinical effects of a new B-complex factor, para-aminobenzioc acid, on pigmentation and fertility. South Med Surg 1942 -March_;104:135-39.
3. Zarafonetis CJD. The treatment of scleroderma: results of potassium para-aminobenzoate therapy 104 cases. In Mills LC, Moyer JH (eds). Inflamation and Diseases of Connective Tissue, W.B. Saunders Co., 1961, 688-96.
4. Zarafonetis CJD et al. Restrospective studies in scleroderma: effect of potassium para-aminobenzoa on survival. J Clin Epidemiol 1988;41:193-205.
5. Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary finding and effect of potassium p-aminobenzoate on vital capacity. Respiration 1989;56:22-33.
6. Clegg DO, Reading JC, Mayes MD, et al. Caparison of aminobenzoate potassium and placebo the treatment of scleroderma. J Rheumatol 1994;21:105-10.
7. Grace WJ et al. Therapy of scleroderma and dermatomyositis. NY State J Med 1963;63:140-44.
8. Zarafonetis CJD, et al. Treatment of pemphigus with potassium para-aminobenzoate. Am J Med S 1956;231:30-50.
9. Sieve BF. Further investigations in the treatment of vitlligo. Virginia Med Monthly 1945 (January):6-17.
10. Hughes CG. Oral PABA and vitiligo. J Am Acad Dermatol 1983;9:770 [letter].
11. Gaby AR. The story of PABA. Nutr Healing 1997;March:3-4, 11 [review].
12. Zarafonetis CJD. Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Derma 1950;15:339-401.
13. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. J Am Acad Dermatol 1985;13:671-2.
14. Worobec S, LaChine A. Dangers of orally administrered para-aminobenzoic acid. JAMA 1984;251:2348.

Choline References:
1. Benjamin J, Levine J. Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084-86.

Biotin References:
1. Said HM, Redha R, Nylander W. Biotin transport in the human intestine: Inhibition by anticonvulsar drugs. Am J Clin Nutr 1989;49:127-31.
2. Zempleni J, Mock DM. Biotin biochemistry and human requirements. J Nutr Biochem 1999;10:128-38 [review].
3. Coggeshall JC et al. Biotin status and plasma glucose in diabetics. Ann NY Acad Sci 1985;447:38
4. Koutsikos D. Agroyannis B, Tzanatos-Exarchou H, Biotin for diabetic peripheral neuropathy. Bio Pharmachother 1990;44:511-14.
5. Hochman LG, Scher RK, Meyerson MS. Brittle nails. Responses to daily biotin supplementation. Curtis 1993;51(4):303-5.
6. Gomer E. The Essential Guide to Vitamins and Mineral New York Harger, 1995;70-72.

Pantothenic Acid References:
1. Fidanza A. Therapeutic action of pantothenic acid. Int J Vit Nutr Res 1983;suppl 24-53-67 [review].


  • Back To List
  • Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home  l  Return to Top of Page

        Nasvhille Chamber of Commerce Dickson County Chamber of Commerce U.S. Commercial Service

    *These statements have not been evaluated by the F.D.A. *USA Laboratories makes no representation or warranties concerning the use of our products for the diagnosis, cure, mitigation, treatment or prevention of any disease. *Seek advice from a health care provider before using this or any supplement product.

    Powered By LionZone Copyright © USA LABORATORIES, INC. All rights reserved.